E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Colorectal Cancer
Liver Metastasis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10052358 |
E.1.2 | Term | Colorectal cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary aim of the New EPOC trial is to determine whether the addition of cetuximab to oxaliplatin plus modified de Gramont or irinotecan plus modified de Gramont combination chemotherapy results in improved progression free survival when compared with combination chemotherapy alone in patients who do not possess a KRAS mutant genotype confirmed by laboratory analysis. |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate overall survival
2. To evaluate quality of life
3. To compare the experimental arm in terms of cost effectiveness in a UK treatment setting
4. To determine whether the addition of cetuximab to combination chemotherapy as above results in improved progression free survival when compared with combination chemotherapy alone in patients who possess the KRAS-wt genotype confirmed by laboratory analysis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Confirmed colorectal adenocarcinoma:
previous or current histologically confirmed primary adenocarcinoma of colon or rectum, together with clinical or radiological evidence of advanced and / or metastatic disease.
• Presence of potentially resectable colorectal cancer liver metastases without detectable extra-hepatic distant disease. Patients with intra-abdominal loco regional recurrence which in the opinion of the surgeon is easily resectable may be included. The following patients are eligible:
Patients who have had long course chemoradiation and R0 surgery for rectal cancer
Patients with rectal cancer who would be suitable for short course radiotherapy as an adjuvant treatment.
Patients with metachronous metastases having undergone complete resection of the primary tumour without gross or microscopic evidence of residual disease (R0).
Patients with synchronous metastases who have undergone R0-resection of the primary tumour more than one month before randomisation.
Patients with synchronous metastases for whom there is sufficient evidence (for example by CT scan or diagnostic laparoscopy) that both the primary tumour and the liver metastases can be completely resected during the same procedure and that resection of primary cancer can be delayed for 3 to 4 months.
Patients who are thought by the hepatic surgeon to be suboptimally resectable are included. This will normally include patients, for instance, who have potentially resectable disease but in whom compromise of the resection margins is likely. These patients are currently normally treated with pre-operative chemotherapy under NICE guidance. This decision will be at the surgeons discretion.
Unidimensionally measurable disease (RECIST criteria, see appendix V) to measure pre-operative response.
• No previous systemic chemotherapy for metastatic disease
adjuvant chemotherapy with 5FU +/- FA, capecitabine or irinotecan may have been given, if completed > 6 months prior to trial entry.
rectal chemoradiotherapy with 5FU +/- FA may have been given, if completed > 1 month prior to trial entry.
• Patients who have received prior oxaliplatin as adjuvant more than six months prior to diagnosis of liver metastases may be offered irinotecan and 5FU instead of oxaliplatin and fluoropyrimidine as neoadjuvant.
• WHO performance status (PS) 0, 1 or 2 (see appendix VII) and considered by responsible consultant to be fit to undergo combination chemotherapy.
• Baseline laboratory tests (within 1 week prior to randomisation):
neutrophils ≥ 1.5 x109/l and platelet count ≥ 100 x109/l
serum bilirubin ≤ 1.25 x upper limit of normal (ULN), alkaline phosphatase ≤ 5 x ULN, and serum transaminase (either AST or ALT) ≤ 2.5 x ULN
estimated creatinine clearance (Cockcroft; appendix VIII) >50ml/min or measured GFR (EDTA clearance) >50 ml/min.
• All patients must be aged 18 years or older.
• For women of childbearing potential, negative pregnancy test and adequate contraceptive precautions. Adequate contraception for men.
• Written informed consent.
• Consent to allow surplus pathological material to be analysed for translational research projects (patients may decline participation in this supplementary component and still participate in the main trial). |
|
E.4 | Principal exclusion criteria |
• Patients who are unfit for the chemotherapy regimens in this protocol, e.g.:
severe uncontrolled concurrent medical illness (including poorly-controlled angina or very recent MI, i.e. in previous 3 months) likely to interfere with protocol treatments.
Any psychiatric or neurological condition which is felt likely to compromise the patient's ability to give informed consent or to comply with oral medication.
Partial or complete bowel obstruction.
Pre-existing neuropathy (> grade 1).
• Patients requiring ongoing treatment with a contraindicated concomitant medication.
• Patients with another previous or current malignant disease which, in the judgement of the treating investigator, is likely to interfere with New EPOC treatment or assessment of response.
• Patients with known hypersensitivity reactions to any of the components of the study treatments.
• Patients with distant metastases outside the liver.
• Female patients who are lactating.
• Patients with a personal or family history suggestive of dihydropyrimidine dehydrogenase (DPD) deficiency or with known DPD deficiency.
• Patients who possess the KRAS-mt genotype or whose KRAS genotype status is unknown in the primary tumour.
• Partial or complete bowel obstruction.
• Chronic diarrhoea or inflammatory bowel disease.
• Gilbert’s syndrome or other congenital abnormality of biliary transport (e.g. Crigler-Najjar syndrome, Dubin-Johnson syndrome).
• Previous transplant surgery, requiring immunosuppressive therapy (due to interaction of cyclosporin-A with irinotecan).
• Patients with ≥ grade 1 residual neurotoxicity following oxaliplatin as adjuvant may be offered irinotecan and 5FU instead of oxaliplatin and fluoropyrimidine as neoadjuvant. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression free survival. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 60 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will occur when the final patient has attended their last follow-up visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 8 |